Table 2.

FUTURE-1 trial results

Endpoint	Percent improvement secukinumab 150 mg n = 202	Percent improvement secukinumab 75 mg n = 202	Placebo n = 202 (%)	P value
Week 24 (total n = 606)
ACR20 score	50	50.5	17.3	P < 0.001 for all comparisons
ACR50 score	34.7	34.7	7.4	P < 0.001 for all comparisons
ACR70 score	18.8	16.8	2.0	P < 0.001 for all comparisons
Week 52 (total n = 507)
ACR20 score	69.5	66.9	–	–
ACR50 score	50.0	38.4	–	–
ACR70 score	28.2	25.6	–	–

ACR20 American College of Rheumatology 20 response, ACR50 American College of Rheumatology 50 response, ACR70 American College of Rheumatology 70 response